Synonyms: AMG-714 | AMG714 | MAb146B7 | PRV-015
Compound class:
Antibody
Comment: Ordesekimab (AMG714, formerly PRV-015) is a fully human anti-IL-15 monoclonal antibody [1]. It binds to Il-15-IL-15Rα complexes on monocytes and disrupts interaction of the cytokine-bound receptor α subunit with the IL-2Rβ and common γ chains of the IL-15 receptor complex that is necessary for receptor activation and downstream signalling.
|
No information available. |
Summary of Clinical Use ![]() |
Ordesekimab (AMG714) is under clinical investigation for efficacy in autoimmune conditions. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02633020 | Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease | Phase 2 Interventional | Amgen | ||
NCT00433875 | Phase 2 AMG 714 in Rheumatoid Arthritis | Phase 2 Interventional | Amgen | ||
NCT04338581 | Evaluation of AMG 714 for Vitiligo | Phase 2 Interventional | National Institute of Allergy and Infectious Diseases (NIAID) |